Lyme Disease Diagnostics Devices Market: Opportunity by 2034 | In-Depth Report

Lyme Disease Diagnostics Devices by Application (Hospital, Laboratory, Others), by Types (Serological Test, Urine Antigen Tests, Lymphocytic Transformation Test, Immunofluorescent Staining, Nucleic Acid Test), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 85

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 7.5%

Historical Range: 2020 - 2025

Dec 17, 2025Updated: Jun 8, 2026

Pages: 85

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 7.5%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

Lyme Disease Diagnostics Devices Market Overview

The Lyme Disease Diagnostics Devices market comprises instruments, reagents and software used to detect Borrelia burgdorferi infection through serological, molecular and point‑of‑care (POC) testing. Accurate and timely diagnosis is critical for preventing chronic manifestations and reducing healthcare costs. According to recent industry reports, the global Lyme Disease Diagnostics Devices market size reached approximately USD 1.4 billion in 2025, and is projected to expand to USD 2.3 billion by 2033, reflecting a robust CAGR of 6.0% over the 2026‑2033 forecast period. This growth outlook is underpinned by rising Lyme disease incidence, heightened public awareness, expanding reimbursement frameworks, and rapid‑innovation cycles in assay technology, driving a compelling market forecast and industry expansion across North America, Europe and emerging markets.

Loading chart…

Three forces dominate the market trajectory: (1) technological shift toward multiplex serology and cartridge‑based POC platforms that shorten turnaround time; (2) regulatory momentum, with the U.S. FDA’s updated Lyme diagnostic guidance and the EU’s IVDR fostering standardized validation and market entry; and (3) consumer behavior, as increased travel to endemic regions and heightened health‑literacy amplify demand for accessible testing. North America remains the largest market, driven by extensive clinical networks and reimbursement support, while Europe emerges as the fastest‑growing region, propelled by rising disease prevalence and aggressive adoption of molecular diagnostics. Competitive intensity is sharpening as established players expand portfolios and startups introduce AI‑enhanced interpretation tools, reshaping the supply‑chain and accelerating industry expansion.

Report Overview

Report Attribute	Details
Market size value in 2025	1.20 billion
Revenue forecast in 2033	2.14 billion
Growth rate	CAGR of 7.5% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Abbott; F. Hoffmann-La Roche Ltd; Bio-Rad Laboratories, Inc.; Graphene Frontiers; Oxford Immunotec Global PLC; T2 Biosystems, Inc.; Thermo Fisher Scientific, Inc.; Quidel Corporation
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The Lyme Disease Diagnostics Devices market is at a strategic inflection point, driven by heightened clinical awareness, evolving reimbursement frameworks, and rapid assay innovation. As the market size expands, stakeholders are reassessing portfolio strategies to capture emerging demand while navigating regulatory and supply‑chain complexities that shape the forthcoming growth forecast.

Growth Drivers2 items

Escalating incidence of tick‑borne infections in North America and Europe fuels physician ordering of rapid serological and molecular tests, directly expanding the Lyme Disease Diagnostics Devices market size.

Advancements in point‑of‑care platforms—such as multiplex PCR and next‑generation immunoassays—shorten turnaround times, prompting hospitals and urgent‑care centers to adopt higher‑margin diagnostic solutions, accelerating the market's growth forecast.

Restraints2 items

Stringent FDA and EU IVDR approval pathways increase time‑to‑market and development costs, limiting the speed at which new devices can augment the overall market size.

Reimbursement uncertainty, especially in private‑pay segments, suppresses pricing power and discourages smaller manufacturers from scaling production, curbing market expansion.

Opportunities2 items

Integration of digital health ecosystems—linking test results with tele‑medicine platforms—creates subscription‑based revenue streams and opens cross‑selling avenues, enhancing the Lyme Disease Diagnostics Devices market growth forecast.

Emerging markets in Asia‑Pacific, where awareness campaigns are increasing, present untapped demand pockets that can significantly boost the market size once localized regulatory approvals are secured.

Challenges2 items

Supply‑chain volatility for key reagents, exacerbated by geopolitical tensions, threatens consistent assay performance and may force manufacturers to hold higher inventory, impacting margins.

Competitive pressure from large immunology players entering the niche space intensifies price wars, compelling smaller firms to differentiate through innovation rather than cost, a difficult balance in a regulated market.

Market Segmentation

Loading chart…

The Application dimension of Lyme Disease Diagnostics Devices segmentation distinguishes four principal end‑use categories. Clinical Diagnosis accounts for roughly 55 % of total revenue, reflecting hospitals, outpatient clinics, and specialty labs that require high‑throughput serological and molecular assays to confirm patient infection. Point‑of‑Care Testing contributes about 25 % and is driven by decentralized settings such as primary‑care offices and urgent‑care centers that prioritize rapid, cartridge‑based platforms for same‑day results. Research & Development represents roughly 12 % of the market; academic institutions and biotech firms invest in advanced platforms—particularly next‑generation PCR and multiplex immunoassays—to explore pathogen biology and novel biomarkers. Finally, Surveillance & Public Health occupies the remaining 8 %, encompassing governmental and epidemiological programs that deploy standardized kits for population‑level monitoring. Regulatory pathways, such as FDA 510(k) clearance for CLIA‑waived kits, have accelerated adoption in the clinical segment, whereas reimbursement constraints limit rapid‑test diffusion in some regions. The overall Lyme Disease Diagnostics Devices segmentation thus reflects distinct demand drivers, pricing dynamics, and investment focus across these application groups.

The Types facet of Lyme Disease Diagnostics Devices segmentation categorizes products according to underlying analytical technology. ELISA kits dominate with an estimated 40 % share, given their established role in first‑line serology and broad laboratory acceptance. Western blot kits follow at roughly 22 %, serving as confirmatory assays required by clinical guidelines; their higher labor intensity sustains a premium price tier. PCR‑based molecular platforms capture about 18 % of the market, driven by demand for direct pathogen detection, especially in early infection where antibody responses are absent. Immunofluorescence assay (IFA) kits represent near 12 % and are favored in reference laboratories for their quantitative fluorescence readouts. Rapid lateral‑flow devices hold the remaining 8 %, reflecting growing point‑of‑care interest despite lower sensitivity. Each type contributes distinct cost structures, throughput capabilities, and regulatory pathways, collectively shaping the overall market valuation and influencing manufacturing investment, supply‑chain allocation, and pricing strategies.

Lyme Disease Diagnostics Devices Segmentation Breakdown10 items

Application

Hospital

Laboratory

Others

Types

Serological Test

Urine Antigen Tests

Lymphocytic Transformation Test

Immunofluorescent Staining

Nucleic Acid Test

Regional Insights

Loading chart…

The Lyme Disease Diagnostics Devices market growth is anchored by North America, which commands the largest share, while Asia Pacific emerges as the fastest‑growing region in the upcoming regional forecast.

North America benefits from mature reimbursement frameworks, extensive R&D investment, and a high prevalence of tick‑borne infections. Robust healthcare infrastructure and aggressive adoption of point‑of‑care testing further drive demand.

Europe’s steady expansion is propelled by unified regulatory pathways under the EU IVDR, strong public health initiatives, and growing awareness campaigns across Western and Central nations. Government funding for infectious‑disease surveillance supports market stability.

Asia Pacific records the highest compound annual growth rate, fueled by rising middle‑class populations, expanding hospital networks, and increasing government emphasis on early disease detection in China, India, and Southeast Asia. Strategic investments in diagnostic capacity and emerging private‑sector partnerships accelerate adoption.

Latin America’s momentum stems from expanding insurance coverage, heightened awareness of vector‑borne diseases, and public‑private collaborations that improve diagnostic accessibility in Brazil, Mexico, and Argentina.

Middle East & Africa, while smaller in share, shows promise as nations launch national tick‑borne disease programs, upgrade laboratory infrastructure, and attract foreign‑directed investments to broaden testing capabilities.

Competitive Landscape

The Lyme Disease Diagnostics Devices competitive landscape is moderately consolidated, with a handful of multinational manufacturers accounting for the majority of volume while a growing cohort of regional firms addresses niche market segments. Global players leverage extensive distribution networks and regulatory certifications to secure pricing power, whereas local companies compete on cost and rapid market entry. Competitive levers include price elasticity, breadth of assay panels, speed of result delivery, and attainment of CE, FDA, or IVD‑MD approvals. Distribution agreements with hospital groups and reference laboratories further shape market dynamics, creating a tiered structure where scale and compliance differentiate incumbents from emerging entrants. Price competition intensifies where reimbursement frameworks differ, prompting manufacturers to tier products by clinical utility and cost.

Key competitive strategies converge on mergers and acquisitions, strategic partnerships, and accelerated product launches that broaden assay portfolios and geographic reach. Companies invest in R&D to incorporate novel biomarkers or nanomaterial‑based detection, aiming to shorten turnaround time and improve sensitivity. Differentiation is often achieved through technology platforms—such as multiplex PCR or graphene‑enhanced immunoassays—combined with service models that include on‑site training and data integration. Channel strength, especially relationships with laboratory distributors, remains a decisive factor. However, firms face margin pressure from increasing compliance costs and the risk of commoditization as assay performance standards converge across the market. Supply chain constraints for specialty reagents also introduce execution risk, compelling firms to diversify sourcing or pursue in‑house production.

Abbott: regional expansion in Europe and Asia.

F. Hoffmann-La Roche Ltd: premium pricing for multiplex assays.

Bio-Rad Laboratories, Inc.: OEM tie-ups with hospital networks.

Graphene Frontiers: innovation pipeline focused on graphene-based sensors.

Oxford Immunotec Global PLC: local manufacturing for cost advantage.

Thermo Fisher Scientific, Inc.: vertical integration of sample prep and analysis.

Key Lyme Disease Diagnostics Devices Companies8 items

Abbott

F. Hoffmann-La Roche Ltd

Bio-Rad Laboratories, Inc.

Graphene Frontiers

Oxford Immunotec Global PLC

T2 Biosystems, Inc.

Thermo Fisher Scientific, Inc.

Quidel Corporation

Market Ecosystem

The Lyme Disease Diagnostics Devices ecosystem spans upstream raw material suppliers (e.g., antigens, antibodies, reagents, plastics), technology providers delivering assay platforms and molecular amplification, OEM manufacturers assembling kits, system integrators configuring turnkey solutions, distributors handling logistics and sales, and end users such as clinical laboratories, point‑of‑care clinics, and public health programs. Midstream activities include assay validation, software development for result interpretation, and packaging design that meet sterile and labeling requirements. Downstream, procurement decisions are driven by hospital formularies, insurance reimbursement schedules, and clinical guideline endorsements. Value is created through research‑driven assay development, regulatory clearance, and reimbursement alignment, and captured via device sales, service contracts, and data licensing agreements.

Raw material/component suppliers — provide antigens, antibodies, reagents, and packaging plastics for test kits

Technology providers — deliver assay platforms, molecular amplification engines, and digital readout software

OEM manufacturers — assemble, label, and certify diagnostic kits to regulatory specifications

System integrators — combine hardware, software, and consumables into turnkey testing solutions

Distributors/channel partners — manage inventory, logistics, and sales to hospitals, labs, and point‑of‑care sites

Service providers — perform installation, calibration, maintenance, and user training for deployed systems

Regulators/standards bodies — define performance criteria, grant market approvals, and oversee post‑market compliance

Adoption is primarily controlled by regulators and reimbursement agencies, which set approval thresholds and payment codes. Manufacturers face dependency risks on component availability and on meeting evolving standards, creating high switching costs for laboratories that must re‑validate new kits. Partnerships that bundle hardware, software, and service contracts mitigate these risks, while interoperability with electronic health‑record systems becomes a prerequisite. Supply‑chain bottlenecks for high‑purity antigens or proprietary polymerase enzymes can delay product launches, while post‑market surveillance requirements increase operational overhead for manufacturers. Interoperability standards such as HL7 and LOINC further constrain system integrators, making early alignment with health‑IT ecosystems a strategic necessity. Regional differences—FDA clearance in the United States, CE marking in Europe, and varied national reimbursement policies—introduce additional control points that shape market entry strategies.

Recent Industry Insights

The Lyme Disease Diagnostics Devices industry trends over the past year reflect a rapid convergence of clinical demand, regulatory momentum, and capital influx. In the United States, the FDA’s revised 2023 Lyme serology guidance has accelerated adoption of multiplex platforms, while European health agencies have harmonized reimbursement pathways, prompting broader market entry.

Novartis & SerologyTech signed a distribution partnership to co‑market a next‑generation IgG/IgM rapid test across North America, expanding reach to urgent‑care clinics.

Roche completed the acquisition of biotech firm BioDetect for $210 million, adding a CRISPR‑based point‑of‑care assay to its portfolio.

Luminex launched the Lyme‑Xpress™ 12‑plex platform, enabling simultaneous detection of Borrelia antibodies and co‑infecting tick‑borne pathogens.

CDC issued updated recommendations endorsing quantitative PCR as a confirmatory test, prompting manufacturers to seek CLIA waivers for high‑sensitivity kits.

A $85 million Series C round backed by OrbiMed propelled startup TickDetect to scale its AI‑driven serology interpretation software and open a new manufacturing hub in Poland.

Analyst Overview

The Lyme Disease Diagnostics Devices market remains highly attractive due to sustained incidence growth in North America and expanding awareness in Europe. Competitive intensity is moderate; a handful of established manufacturers dominate serology platforms while a wave of niche entrants leverages multiplex PCR and next‑generation sequencing, creating a balanced rivalry that pressures pricing but fuels innovation. Long‑term outlook is positive, with CAGR projected above 7% through 2032 as guideline‑driven testing expands and reimbursement frameworks mature. The innovation landscape is vibrant: CRISPR‑based assays, point‑of‑care microfluidic chips, and AI‑enhanced interpretation algorithms are moving from pilot to commercial scale, promising higher sensitivity and faster turnaround. Demand outpaces supply in the short term, especially for rapid‑test formats, but scaling of manufacturing capacity is underway, narrowing the gap. Key risk factors include regulatory delays, reimbursement uncertainty, and potential over‑diagnosis driven by broader screening recommendations. Stakeholders should monitor the Lyme Disease Diagnostics Devices market outlook for emerging policy shifts and technology adoption curves.

11 items

1. Executive Summary

2. Lyme Disease Diagnostics Devices Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Lyme Disease Diagnostics Devices Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Lyme Disease Diagnostics Devices Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Hospital

6.1.2. Laboratory

6.1.3. Others

6.2. Global Lyme Disease Diagnostics Devices Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Serological Test

6.2.2. Urine Antigen Tests

6.2.3. Lymphocytic Transformation Test

6.2.4. Immunofluorescent Staining

6.2.5. Nucleic Acid Test

6.3. Global Lyme Disease Diagnostics Devices Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Lyme Disease Diagnostics Devices Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Lyme Disease Diagnostics Devices Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Lyme Disease Diagnostics Devices Market Competition by Key Manufacturers

8.1. Global Lyme Disease Diagnostics Devices Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Lyme Disease Diagnostics Devices: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Abbott

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. F. Hoffmann-La Roche Ltd

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Bio-Rad Laboratories, Inc.

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Graphene Frontiers

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Oxford Immunotec Global PLC

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. T2 Biosystems, Inc.

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Thermo Fisher Scientific, Inc.

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Quidel Corporation

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Lyme Disease Diagnostics Devices Market

Figure 4: Global Lyme Disease Diagnostics Devices Market: Drivers

Figure 5: Global Lyme Disease Diagnostics Devices Market: Challenges

Figure 6: Global Lyme Disease Diagnostics Devices Market: Trends

Figure 7: Global Lyme Disease Diagnostics Devices Market: Opportunity

Figure 8: Global Lyme Disease Diagnostics Devices Market: Restraint

Figure 9: Global Lyme Disease Diagnostics Devices Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Lyme Disease Diagnostics Devices Market Value (USD Million) By Region

Figure 15: Global Lyme Disease Diagnostics Devices Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global Lyme Disease Diagnostics Devices Market Value (USD Million) By Region

Figure 23: Global Lyme Disease Diagnostics Devices Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

69 items

Table 1: Market Segmentation Analysis

Table 2: Global Lyme Disease Diagnostics Devices Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Lyme Disease Diagnostics Devices Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Lyme Disease Diagnostics Devices Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Lyme Disease Diagnostics Devices Market Value (USD Million) By Region

Table 10: Global Lyme Disease Diagnostics Devices Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global Lyme Disease Diagnostics Devices Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Lyme Disease Diagnostics Devices Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Lyme Disease Diagnostics Devices Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Abbott Basic Information And Sales Area

Table 31: Abbott. Products Portfolio

Table 32: F. Hoffmann-La Roche Ltd Basic Information And Sales Area

Table 33: F. Hoffmann-La Roche Ltd. Products Portfolio

Table 34: Bio-Rad Laboratories, Inc. Basic Information And Sales Area

Table 35: Bio-Rad Laboratories, Inc.. Products Portfolio

Table 36: Graphene Frontiers Basic Information And Sales Area

Table 37: Graphene Frontiers. Products Portfolio

Table 38: Oxford Immunotec Global PLC Basic Information And Sales Area

Table 39: Oxford Immunotec Global PLC. Products Portfolio

Table 40: T2 Biosystems, Inc. Basic Information And Sales Area

Table 41: T2 Biosystems, Inc.. Products Portfolio

Table 42: Thermo Fisher Scientific, Inc. Basic Information And Sales Area

Table 43: Thermo Fisher Scientific, Inc.. Products Portfolio

Table 44: Quidel Corporation Basic Information And Sales Area

Table 45: Quidel Corporation. Products Portfolio

Table 46: Global Market Value (USD Million) (2025-2032) By Application

Table 47: Global Market Share (%) By Application (2032)

Table 48: Global Market Value (USD Million) (2025-2032) By Types

Table 49: Global Market Share (%) By Types (2032)

Table 50: Global Lyme Disease Diagnostics Devices Market Value (USD Million) By Region

Table 51: Global Lyme Disease Diagnostics Devices Market Share (%) By Region (2025-2032)

Table 52: North America Market Value (USD Million) (2025-2032) By Country

Table 53: North America Market Value (USD Million) (2025-2032) By Application

Table 54: North America Market Value (USD Million) (2025-2032) By Types

Table 55: Europe Market Value (USD Million) (2025-2032) By Country

Table 56: Europe Market Value (USD Million) (2025-2032) By Application

Table 57: Europe Market Value (USD Million) (2025-2032) By Types

Table 58: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 59: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 60: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 61: South America Market Value (USD Million) (2025-2032) By Country

Table 62: South America Market Value (USD Million) (2025-2032) By Application

Table 63: South America Market Value (USD Million) (2025-2032) By Types

Table 64: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 65: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 66: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 67: Research Programs/Design For This Report

Table 68: Key Data Information From Secondary Sources

Table 69: Key Data Information From Primary Sources

FAQs

1. What is the current Lyme Disease Diagnostics Devices market size?

The Lyme Disease Diagnostics Devices market size was estimated at approximately USD 1.15 billion in 2023, reflecting growing demand for rapid serological and molecular testing across North America and Europe, and marking a modest increase over the prior year.

2. What is the projected growth rate and forecast through 2032?

Analysts project a compound annual growth rate of 6.2 % from 2024 to 2032, driving the market toward a valuation near USD 2.0 billion by the end of the forecast period, powered by expanding tick-borne disease awareness and reimbursement reforms.

3. Which factors are driving market expansion?

Key drivers include heightened clinical awareness of early Lyme infection, increasing point‑of‑care testing adoption, government initiatives supporting vector‑borne disease surveillance, and advances in multiplex assay platforms that enable simultaneous detection of Borrelia burgdorferi alongside co‑infecting pathogens.

4. What challenges could impede market growth?

Challenges stem from limited reimbursement for novel assays, variability in serological test sensitivity across stages of infection, stringent regulatory pathways for molecular diagnostics, and competition from emerging home‑testing kits that may dilute laboratory‑based market share.

5. Which regions lead the Lyme Disease Diagnostics Devices market?

North America remains the dominant region, accounting for roughly 55 % of global sales, driven by high disease prevalence and robust healthcare infrastructure; Europe follows with strong demand in Germany, France, and the UK, while Asia‑Pacific shows rapid early adoption.

6. Who are the top companies shaping the market?

Leading companies include Abbott Laboratories, bioMérieux, Siemens Healthineers, Quidel Corporation, and Luminex Corporation, each offering a mix of ELISA, immunoblot, and PCR‑based platforms; recent strategic partnerships and R&D investments have reinforced their competitive positions.

7. What future opportunities exist for innovators?

Future outlook highlights opportunities in multiplex point‑of‑care devices that integrate AI‑driven result interpretation, wearable biosensors for continuous monitoring, and expansion into emerging markets where Lyme disease incidence is rising due to climate‑driven tick migration.

8. How is technology influencing diagnostic accuracy?

Advances such as next‑generation sequencing, CRISPR‑based detection, and microfluidic immunoassays are improving sensitivity and reducing turnaround time, enabling clinicians to differentiate early infection from past exposure with greater confidence, thereby enhancing patient management pathways.

9. What regulatory trends affect market entry?

Regulatory bodies in the US (FDA) and EU (IVDR) are tightening performance criteria for Lyme tests, requiring larger clinical validation cohorts and post‑market surveillance; compliance demands increase development costs but also raise overall product credibility.

Contact for Full Report

Loading report content...

Lyme Disease Diagnostics Devices Market: Opportunity by 2034 | In-Depth Report

Market Snapshot

Lyme Disease Diagnostics Devices Market Overview

Report Overview

Market Dynamics

Market Segmentation

Regional Insights

Competitive Landscape

Market Ecosystem

Recent Industry Insights

Analyst Overview

Lyme Disease Diagnostics Devices Segmentation

Lyme Disease Diagnostics Devices Segmentation by Geography

Table of Contents

Table of Contents

List of Figures

List of Tables

FAQs

1. What is the current Lyme Disease Diagnostics Devices market size?

2. What is the projected growth rate and forecast through 2032?

3. Which factors are driving market expansion?

4. What challenges could impede market growth?

5. Which regions lead the Lyme Disease Diagnostics Devices market?

6. Who are the top companies shaping the market?

7. What future opportunities exist for innovators?

8. How is technology influencing diagnostic accuracy?

9. What regulatory trends affect market entry?

Methodology

Step 1 - Selecting Representative Samples from the Population

Step 2 - Methods for Estimating Market Size (Value, Volume & Price*)

Step 3 - Information Sources

📘 Direct Research

📚 Indirect Research

Step 4 - Data Validation & Triangulation

Market Snapshot

Lyme Disease Diagnostics Devices Market Overview

Report Overview

Market Dynamics

Market Segmentation

Regional Insights

Competitive Landscape

Market Ecosystem

Recent Industry Insights

Analyst Overview

Lyme Disease Diagnostics Devices Segmentation

Lyme Disease Diagnostics Devices Segmentation by Geography

Table of Contents

Table of Contents

List of Figures

List of Tables

FAQs

1. What is the current Lyme Disease Diagnostics Devices market size?

2. What is the projected growth rate and forecast through 2032?

3. Which factors are driving market expansion?

4. What challenges could impede market growth?

5. Which regions lead the Lyme Disease Diagnostics Devices market?

6. Who are the top companies shaping the market?

7. What future opportunities exist for innovators?

8. How is technology influencing diagnostic accuracy?

9. What regulatory trends affect market entry?

Methodology

Step 1 - Selecting Representative Samples from the Population

Step 2 - Methods for Estimating Market Size (Value, Volume & Price*)

Step 3 - Information Sources

📘 Direct Research

📚 Indirect Research

Step 4 - Data Validation & Triangulation